Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Espie

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Drug Metabolism Reviews|July 16, 2009
Gender and interindividual variability in pharmacokineticsJean-Marie Nicolas, Pascal Espie, Mathieu Molimard
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 13, 2018
Nonclinical Safety Assessment of CFZ533, a Fc-Silent Anti-CD40 Antibody, in Cynomolgus MonkeysPeter Ulrich, Thierry Flandre, Pascal Espie, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2019
A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept TrialGeorge J Kahaly, Marius Nicolae Stan, Lara Frommer, et al.
British Journal of Clinical Pharmacology|April 22, 2026
Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studiesAlexandra A J Sillé, Juliette A van den Noort, Iva Lelios, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 18, 2018
Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibodyJacinda Ristov, Pascal Espie, Peter Ulrich, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Drug Metabolism Reviews|July 16, 2009
Gender and interindividual variability in pharmacokineticsJean-Marie Nicolas, Pascal Espie, Mathieu Molimard
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 13, 2018
Nonclinical Safety Assessment of CFZ533, a Fc-Silent Anti-CD40 Antibody, in Cynomolgus MonkeysPeter Ulrich, Thierry Flandre, Pascal Espie, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2019
A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept TrialGeorge J Kahaly, Marius Nicolae Stan, Lara Frommer, et al.
British Journal of Clinical Pharmacology|April 22, 2026
Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studiesAlexandra A J Sillé, Juliette A van den Noort, Iva Lelios, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 18, 2018
Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibodyJacinda Ristov, Pascal Espie, Peter Ulrich, et al.
Pageof 1